Table 2.

OTUD5 was correlated with clinical pathologic characteristics of NSCLC patients.

	LUAD OTUD5			LUSC OTUD5
	High	Low	p-value	High	Low	p-value
Age
≥60	178	185	0.530	195	193	0.738
<60	72	66		42	45
Sex
Male	121	119	0.860	182	176	0.534
Female	139	141		60	66
Tabaco smoking history
Stage3-5	154	155	0.927	147	180	0.001*
Stage1-2	99	98		90	57
Other malignancy history
Negative	209	219	0.250	207	223	0.027*
Positive	51	41		34	19
Laterality
Left	98	104	0.611	94	111	0.118
Right	154	149		133	117
Location of lung parenchyma
Peripheral lung	65	61	0.539	44	47	0.687
Central lung	30	34		73	70
Residual tumors
Negative (R0)	173	173	1.000	195	191	0.307
Positive (R1/R2)	9	9		6	10
Tumor size
T1	89	83	0.554	65	43	0.016*
T2-T4	169	176		177	199
Lymph node stage
Negative	177	156	0.049*	161	146	0.152
Positive	77	98		78	93
Distant metastasis
Negative	179	173	0.205	198	196	0.255
Positive	9	15		2	5
Tumor TNM Stagea
I–II	215	187	0.002*	160	139	0.048*
III–IV	41	69		80	101

The cutoff value for OTUD5 mRNA expression was set at 10.

NSCLC non-small-cell lung carcinoma, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma.

^aTumor TNM stage was stratified as I-IIA and IIB-IV for the LUSC patients. The Chi-square test was performed to analyze the relationship between OTUD5 expression level and demographic and clinical pathological parameters. All p-values were two sided and the level of statistical significance was set at < 0.05. *p < 0.05.